Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Influenza vaccine immune response in idelalisib-treated B-cell malignancies
2017-003055-30Phase 2Terminated
- Sponsor
- Gilead Sciences
- Start
- May 2018
- Modality
- Small Molecules, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of idelalisib and influenza vaccine in B-cell malignancy and non-Hodgkin lymphoma (NHL), sponsored by Gilead Sciences. Primary endpoint: Seroconversion rate. Started May 2018; status: terminated.
02
Drugs
idelalisibinfluenza vaccine
03
Conditions
B-cell malignancynon-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on 2017-003055-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003055-30.